

Supplementary Table 1. Baseline characteristics and outcomes by age of onset in ulcerative colitis patients

Characteristic	Age, yr				p value
	1–19 (n = 55)	20–39 (n = 492)	40–59 (n = 453)	≥ 60 (n = 141)	
Age of diagnosis, yr	17.8 ± 2.4	30.9 ± 5.4 ^a	48.7 ± 5.3 ^{a,b}	67.0 ± 5.3 ^{a,b,c}	0.000
Sex					0.938
Male	29 (52.7)	277 (56.3)	259 (57.2)	80 (56.7)	
Female	26 (47.3)	215 (43.7)	194 (42.8)	61 (43.3)	
Body mass index, kg/m ²	19.8 ± 2.8	21.8 ± 3.0 ^a	22.9 ± 3.1 ^{a,b}	22.5 ± 3.3 ^{a,b}	0.243
Family history of IBD	1/45 (2.2)	7/387 (1.8)	3/377 (0.8)	2/122 (1.6)	0.628
Smoking	2/36 (5.6)	68/317 (21.5) ^a	84/307 (27.4) ^a	32/102 (31.4) ^{a,b}	0.006
Follow-up duration, yr	7.0 ± 3.9	7.4 ± 4.2	7.1 ± 4.3	6.5 ± 3.9	0.624
Mayo score at diagnosis	7.7 ± 3.0	5.8 ± 2.7 ^a	5.4 ± 2.7 ^a	5.5 ± 2.6 ^a	0.389
Disease activity at diagnosis					0.000
Mild (3–5)	8/35 (22.9)	157/327 (48.0) ^a	183/305 (60.0) ^{a,b}	50/94 (53.2) ^a	
Moderate (6–10)	17/35 (48.6)	132/327 (40.4)	91/305 (29.8) ^b	38/94 (40.4)	
Severe (11–12)	10/35 (28.6)	38/327 (11.6) ^a	31/305 (10.2) ^a	6/94 (6.4) ^a	
Montreal classification of extent of UC					0.000
E1 (ulcerative proctitis)	15 (27.3)	209 (42.5) ^a	210 (46.4) ^a	67 (47.5) ^a	
E2 (left-sided UC)	11 (20.0)	128 (26.0)	144 (31.8)	48 (34.0)	
E3 (extensive UC)	29 (52.7)	155 (31.5) ^a	99 (21.9) ^{a,b}	26 (18.5) ^{a,b}	
UC-related admission	29 (52.7)	192 (39.0)	186 (41.1)	65 (46.1)	0.147
UC-related operation	4 (7.3)	22 (4.5)	27 (6.0)	10 (7.1)	0.533
Medication					
Oral steroids	19 (34.5)	212 (43.1)	206 (45.5)	56 (39.7)	0.343
IV steroids	23 (41.8)	95 (19.3) ^a	70 (15.5) ^a	31 (22.0) ^a	0.000
Immunosuppressants	26 (47.3)	146 (29.7) ^a	111 (24.5) ^a	35 (24.8) ^a	0.003
Infliximab	11 (20.0)	40 (8.1) ^a	31 (6.8) ^a	7 (5.0) ^a	0.003
Severe outcomes	24 (43.6)	122 (24.8) ^a	97 (21.4) ^a	37 (26.2) ^a	0.004

Values are presented as mean ± SD or number (%).

IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous.

^ap < 0.05 compared with the 1–19 group.

^bp < 0.05 compared with the 20–39 group.

^cp < 0.05 compared with the 40–59 group.